DanCann Pharma AS - Unit (5 Ordinary sha

NEW
XSAT:DANCAN (Denmark)   Unit (5 Ordinary shares & 2 Wrts)
kr 0.003 (0%) Dec 12
At Loss
P/B:
0.33
Market Cap:
kr 11.37M ($ 1.59M)
Enterprise V:
kr 11.17M ($ 1.57M)
Volume:
66.78M
Avg Vol (2M):
95.36M
Warning! GuruFocus detected 5 Severe warning signs with DANCAN. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
66.78M
Market Cap kr:
11.37M
Market Cap $:
1.59M
At Loss
Avg Vol (2M):
95.36M
Enterprise Value kr:
11.17M
Enterprise Value $:
1.57M
PB Ratio:
0.33
Website Sources Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

DanCann Pharma AS

ISIN : DK0061410487
https://www.dancann.com
Rugvaenget 5, Ansager, DNK, DK-6823

Share Class Description:

XSAT:DANCAN: Unit (5 Ordinary shares & 2 Wrts)
Compare
Compare
XSAT:ARCEDEXSAT:ACUCOSTO:GABAOSTO:EMPLIZTSXTER:MRKTSE:4502LSE:HLNNSE:SUNPHARMATSE:4523TSE:4507SZSE:000538XSWX:SDZHKSE:03692NBIXNSE:DIVISLABBOM:500124VTRSSZSE:000963XPAR:IPN
Traded in other countries / regions
DANCAN.SwedenDAN.GermanyDCPXF.USA
IPO Date
2020-11-12
Description
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.03
Equity-to-Asset 0.85
Debt-to-Equity 0.44
Debt-to-EBITDA -0.89
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -8.55
Distress
Grey
Safe
Beneish M-Score -17.11
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 54.6
3-Year EPS without NRI Growth Rate 34.7
3-Year FCF Growth Rate 70.4
3-Year Book Growth Rate -79.3

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 29.72
9-Day RSI 37.56
14-Day RSI 41.39
3-1 Month Momentum % -55.26
6-1 Month Momentum % -93.33
12-1 Month Momentum % -66.16

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.26
Quick Ratio 1.24
Cash Ratio 0.08
Days Inventory 8.53
Days Sales Outstanding 139.18
Days Payable 61.29

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -187.7
Shareholder Yield % 14.46

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % -9.71
Operating Margin % -118.5
Net Margin % -701.19
FCF Margin % -61.5
ROE % -309.29
ROA % -213.24
ROIC % -34.66
3-Year ROIIC % 275.14
ROC (Joel Greenblatt) % -1136.1
ROCE % -285.45

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 0.3
PB Ratio 0.33
EV-to-EBIT -0.21
EV-to-EBITDA -1.69
EV-to-Revenue 1.35
EV-to-FCF -2.19
Price-to-GF-Value 0.15
Earnings Yield (Greenblatt) % -476.19
FCF Yield % -44.9

Financials (Next Earnings Date:2025-02-28 Est.)

XSAT:DANCAN's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

DanCann Pharma AS Executives

Details

GF Value: kr0.02

XSAT:DANCAN

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 8.303
EPS (TTM) (kr) -0.115
Beta -
3-Year Sharpe Ratio -0.04
3-Year Sortino Ratio -0.07
Volatility % 272.34
14-Day RSI 41.39
14-Day ATR (kr) 0.00219
20-Day SMA (kr) 0.00586
12-1 Month Momentum % -66.16
52-Week Range (kr) 0.0026 - 0.091
Shares Outstanding (Mil) 3,791.1

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

DanCann Pharma AS Filings

Filing Date Document Date Form
No Filing Data

DanCann Pharma AS Stock Events

Financials Calendars
Event Date Price (kr)
No Event Data

DanCann Pharma AS Frequently Asked Questions

What is DanCann Pharma AS(XSAT:DANCAN)'s stock price today?
The current price of XSAT:DANCAN is kr0.00. The 52 week high of XSAT:DANCAN is kr0.09 and 52 week low is kr0.00.
When is next earnings date of DanCann Pharma AS(XSAT:DANCAN)?
The next earnings date of DanCann Pharma AS(XSAT:DANCAN) is 2025-02-28 Est..
Does DanCann Pharma AS(XSAT:DANCAN) pay dividends? If so, how much?
DanCann Pharma AS(XSAT:DANCAN) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.